|Siplizumab (Code C38685)|
|Terms & Properties|
Preferred Name: Siplizumab
Definition: A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.
NCI-GLOSS Definition: A monoclonal antibody that is being studied in the treatment of certain lymphoproliferative disorders and psoriasis.
NCI Metathesaurus Link: C1328709 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|PDQ Closed Trial Search ID||346499|
|PDQ Open Trial Search ID||346499 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|